Q: What is the WHO Global Breast Cancer Initiative?

The WHO GBCI (2021-2030) is a flagship initiative targeting: 60% of women diagnosed at Stage I or II; 80% receiving complete staging; and 80% completing recommended treatment — to avert 2.5 million deaths by 2040. It focuses on LMICs with the largest mortality gaps, targeting health promotion (awareness of symptoms), early detection (clinical breast examination, navigation to diagnosis) and timely treatment (multi-disciplinary, guideline-based). It recognises that universal mammography screening is not appropriate in all settings.

Q: What treatments exist for breast cancer?

Breast cancer treatment is individualised based on tumour subtype, stage and patient factors. Options include: surgery (breast-conserving surgery or mastectomy); radiotherapy; chemotherapy; hormone therapy (tamoxifen, aromatase inhibitors for hormone receptor-positive cancers); HER2-targeted therapy (trastuzumab/Herceptin for HER2-positive cancers); immunotherapy (pembrolizumab for TNBC); and CDK4/6 inhibitors (palbociclib, ribociclib for metastatic hormone receptor-positive disease). Multi-disciplinary team care in specialised centres achieves best outcomes.

Q: What is triple-negative breast cancer?

Triple-negative breast cancer (TNBC) lacks oestrogen receptor, progesterone receptor and HER2 overexpression — making it unresponsive to hormone therapy and HER2-targeted therapy. It accounts for 10-15% of breast cancers but is disproportionately aggressive, affects younger women, has higher rates in women of African ancestry, and carries higher recurrence rates within the first 3-5 years. Chemotherapy and immunotherapy (pembrolizumab) are the primary treatments.

Q: Is mammography the best screening method?

For high-resource settings, organised biennial mammography screening for women aged 50-69 reduces breast cancer mortality by approximately 20% and is recommended by WHO, IARC and most high-income country guidelines. However, mammography requires significant infrastructure, trained radiologists and follow-up systems — making it inappropriate for universal rollout in many LMICs. WHO recommends clinical breast examination (CBE) as the primary early detection tool in settings without mammography, combined with health promotion and rapid referral pathways.

Q: How does breastfeeding affect breast cancer risk?

Breastfeeding reduces breast cancer risk: the lifetime risk reduction is approximately 4.3% per 12 months of cumulative breastfeeding — with greater risk reduction for longer total breastfeeding. The mechanism includes: hormonal changes (reduced oestrogen exposure); differentiation of breast tissue; and elimination of potential carcinogens in breast secretions. This is one of the population-level reasons breastfeeding promotion is also a cancer prevention strategy.

Q: What is the access gap for treatment in LMICs?

The treatment gap for breast cancer in LMICs is profound: HER2-targeted therapy (trastuzumab) costs $25,000-50,000 per year in high-income countries — completely unaffordable in LMICs. CDK4/6 inhibitors are similarly inaccessible. Even standard chemotherapy and hormone therapy are intermittently available in many LMICs due to supply chain challenges. Surgery and radiotherapy capacity is severely limited. Access to breast cancer treatment in LMICs is a major global health equity issue.

Question 1

How common is breast cancer?

Accepted Answer

Breast cancer is the most common cancer globally: 2.3 million new cases and 685,000 deaths in 2020. Since 2021 it has overtaken lung cancer to become the world's most common cancer overall. It is the most common cancer in women in the vast majority of countries — accounting for 1 in 4 female cancers. Incidence is rising in every world region, including LMICs, as risk factors (obesity, late pregnancy, reduced breastfeeding) increase with lifestyle change.

Question 2

What are the symptoms of breast cancer?

Accepted Answer

The most common early signs: a painless lump or thickening in the breast or armpit; change in breast size or shape; dimpling or puckering of the breast skin (peau d'orange); nipple discharge (bloody, especially from one nipple); nipple inversion; redness or rash on the breast or nipple; persistent breast or nipple pain. Approximately 90% of breast lumps are benign — but any lump or change should be assessed by a healthcare provider promptly.

Question 3

What are BRCA1 and BRCA2?

Accepted Answer

BRCA1 and BRCA2 are tumour suppressor genes — when functioning normally, they help repair DNA damage. Inherited mutations in BRCA1 carry a 45-72% lifetime breast cancer risk and 44% ovarian cancer risk; BRCA2 mutations carry 45-85% breast cancer risk. BRCA-positive women can opt for enhanced surveillance (annual MRI plus mammography), chemoprevention (tamoxifen) or prophylactic surgery (mastectomy, oophorectomy). Genetic testing is recommended for women with strong family history.

Question 4

What is the survival difference between early and late diagnosis?

Accepted Answer

Stage determines survival dramatically. Five-year survival: Stage I (localised) >99%; Stage II approximately 90%; Stage III approximately 70%; Stage IV (metastatic) approximately 29%. Yet in many LMICs, 60-80% of women present at Stage III or IV — compared to <20% in high-income countries. The primary driver is absence of early detection programmes and low awareness. Reducing the stage at diagnosis is the single most impactful intervention for LMIC breast cancer mortality.

Question 5

What is the WHO Global Breast Cancer Initiative?

Accepted Answer

The WHO GBCI (2021-2030) is a flagship initiative targeting: 60% of women diagnosed at Stage I or II; 80% receiving complete staging; and 80% completing recommended treatment — to avert 2.5 million deaths by 2040. It focuses on LMICs with the largest mortality gaps, targeting health promotion (awareness of symptoms), early detection (clinical breast examination, navigation to diagnosis) and timely treatment (multi-disciplinary, guideline-based). It recognises that universal mammography screening is not appropriate in all settings.

Question 6

What treatments exist for breast cancer?

Accepted Answer

Breast cancer treatment is individualised based on tumour subtype, stage and patient factors. Options include: surgery (breast-conserving surgery or mastectomy); radiotherapy; chemotherapy; hormone therapy (tamoxifen, aromatase inhibitors for hormone receptor-positive cancers); HER2-targeted therapy (trastuzumab/Herceptin for HER2-positive cancers); immunotherapy (pembrolizumab for TNBC); and CDK4/6 inhibitors (palbociclib, ribociclib for metastatic hormone receptor-positive disease). Multi-disciplinary team care in specialised centres achieves best outcomes.

Question 7

What is triple-negative breast cancer?

Accepted Answer

Triple-negative breast cancer (TNBC) lacks oestrogen receptor, progesterone receptor and HER2 overexpression — making it unresponsive to hormone therapy and HER2-targeted therapy. It accounts for 10-15% of breast cancers but is disproportionately aggressive, affects younger women, has higher rates in women of African ancestry, and carries higher recurrence rates within the first 3-5 years. Chemotherapy and immunotherapy (pembrolizumab) are the primary treatments.

Question 8

Is mammography the best screening method?

Accepted Answer

For high-resource settings, organised biennial mammography screening for women aged 50-69 reduces breast cancer mortality by approximately 20% and is recommended by WHO, IARC and most high-income country guidelines. However, mammography requires significant infrastructure, trained radiologists and follow-up systems — making it inappropriate for universal rollout in many LMICs. WHO recommends clinical breast examination (CBE) as the primary early detection tool in settings without mammography, combined with health promotion and rapid referral pathways.

Question 9

How does breastfeeding affect breast cancer risk?

Accepted Answer

Breastfeeding reduces breast cancer risk: the lifetime risk reduction is approximately 4.3% per 12 months of cumulative breastfeeding — with greater risk reduction for longer total breastfeeding. The mechanism includes: hormonal changes (reduced oestrogen exposure); differentiation of breast tissue; and elimination of potential carcinogens in breast secretions. This is one of the population-level reasons breastfeeding promotion is also a cancer prevention strategy.

Question 10

What is the access gap for treatment in LMICs?

Accepted Answer

The treatment gap for breast cancer in LMICs is profound: HER2-targeted therapy (trastuzumab) costs $25,000-50,000 per year in high-income countries — completely unaffordable in LMICs. CDK4/6 inhibitors are similarly inaccessible. Even standard chemotherapy and hormone therapy are intermittently available in many LMICs due to supply chain challenges. Surgery and radiotherapy capacity is severely limited. Access to breast cancer treatment in LMICs is a major global health equity issue.

Question 11

What is October as Breast Cancer Awareness Month?

Accepted Answer

October is Breast Cancer Awareness Month (BCAM) — an annual health awareness campaign founded in 1985, now the most widely recognised cancer awareness campaign globally. It has raised hundreds of millions for research and substantially increased public awareness of breast cancer symptoms and the importance of early detection. Organisations including WHO, UICC, Susan G. Komen, Breast Cancer Now and the Pink Ribbon campaign coordinate BCAM activities globally.

Question 12

How does GMJ News cover breast cancer?

Accepted Answer

GMJ News tracks WHO GBCI progress, GLOBOCAN incidence and mortality data, trial results for new therapies, mammography policy and access equity. Breast cancer rates in Georgia and the South Caucasus — with increasingly westernised risk factor profiles — are a direct public health concern for PHIG and the Georgian Medical Journal.

GMJ News

Breast Cancer

Key messages

Key statistics

Glossary of key terms

Latest GMJ coverage

Frequently asked questions 12 Q&A — structured for Google featured snippets and AI discovery

Knowledge hub: guidelines, conventions and reports

Organizations working in migration and health

Related health topics

Company